Balyasny Asset Management LLC Dexcom Inc Call Options Transaction History

Balyasny Asset Management LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$64.0 - $116.06 $1.41 Million - $2.55 Million	22,000 New	22,000 $1.47 Million
Q1 2023 May 15, 2023	BUY	$104.0 - $122.92 $52.2 Million - $61.7 Million	501,900 Added 2772.93%	520,000 $60.4 Million
Q4 2022 Feb 14, 2023	SELL	$84.98 - $122.67 $348,418 - $502,947	-4,100 Reduced 18.47%	18,100 $2.05 Million
Q3 2022 Nov 14, 2022	SELL	$76.35 - $94.18 $290,130 - $357,884	-3,800 Reduced 14.62%	22,200 $1.79 Million
Q2 2022 Aug 15, 2022	SELL	$67.99 - $132.89 $5.83 Million - $11.4 Million	-85,800 Reduced 76.74%	26,000 $1.94 Million
Q3 2018 Nov 14, 2018	SELL	$23.35 - $36.72 $1.04 Million - $1.63 Million	-44,400 Reduced 28.43%	111,800 $15.5 Million
Q4 2017 Feb 14, 2018	BUY	$11.12 - $15.38 $1.51 Million - $2.09 Million	136,200 Added 681.0%	156,200 $8.96 Million
Q3 2017 Nov 14, 2017	BUY	$11.36 - $18.98 $227,200 - $379,600	20,000	20,000 $979,000

1,014

351M

5.51M

5.6M

Ticker DXCM
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 386,257,984
Market Cap $31B
Description
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM ...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.